Tretinoin

Summary

Tretinoin (CHEMBL38) is an approved small-molecule keratolytic drug (ATC D10AD51) targeting RARA, RARB, and RARG; indicated across 45 conditions including acne and neoplasm; with CIViC clinical evidence for 12 variant-indication associations (e.g. PML::RARA Fusion in acute promyelocytic leukemia).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D10AD51 (+2 more)
• Targets: 7 (RARA, RARB, RARG…)
• Indications: 45 conditions
• Clinical trials: 154
• Precision-oncology evidence (CIViC): 12 variant–indication associations
• Chemistry: 300.4 Da · C20H28O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL38
Name	Tretinoin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	444795
ChEBI	CHEBI:15367
ATC	D10AD51, L01XF01, D10AD01
Molecular formula	C20H28O2
Molecular weight	300.4
InChIKey	SHGAZHPCJJPHSC-YCNIQYBTSA-N

SMILES: CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C

IUPAC name: (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid

ChEBI definition: A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.

Pharmacological roles (ChEBI): keratolytic drug, antineoplastic agent, antioxidant, signalling molecule, retinoid X receptor agonist, anti-inflammatory agent, AP-1 antagonist, retinoic acid receptor agonist.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Aberel, Acticin, All-trans retinoic acid, All-trans-retinoic acid, Altreno, Atralin, Avita, Eudyna, Kerlocal, NSC-122758, Oristar rna, Renova

Parent form; salt/anhydrous children: CHEMBL2051965

Patent coverage: 55,679 distinct patent families (194,008 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
RARA	Retinoic acid receptor-α	Agonist	7.77	0.8%	P10276
RARB	Retinoic acid receptor-β	Agonist	9.4	0.1%	P10826
RARG	Retinoic acid receptor-γ	Agonist	9.6	1.6%	P13631
PPARD	Peroxisome proliferator-activated receptor-β/δ	Full agonist	7.8	0.6%	Q03181
RORB	RAR-related orphan receptor-β	Agonist		0.1%	Q92753
NR2C2	Testicular receptor 4	Full agonist	4.62	1.1%	P49116
NR2E1	TLX	Agonist	5.74	0.5%	Q9Y466

Broader ChEMBL bioactivity targets: 51 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Geminin, Nuclear receptor ROR-gamma.

Bioactivity

ChEMBL activities: 237 potent at pChembl ≥ 5 of 265 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
RARG	10.4	Ki	0.04	nM	CHEMBL_ACT_657655
RARA	10	Ki	0.1	nM	CHEMBL_ACT_194095
RORB	9.82	IC50	0.15	nM	CHEMBL_ACT_14551303
RARG	9.7	Kd	0.2	nM	CHEMBL_ACT_1612380
RARG	9.7	EC50	0.2	nM	CHEMBL_ACT_2616029
P18911	9.66	EC50	0.22	nM	CHEMBL_ACT_18488910
RARG	9.52	Kd	0.3	nM	CHEMBL_ACT_755979
RARB	9.4	Ki	0.4	nM	CHEMBL_ACT_194093
P62965	9.4	Kd	0.4	nM	CHEMBL_ACT_347449
RXRA	9.4	Ki	0.4	nM	CHEMBL_ACT_663250
RARB	9.4	Kd	0.4	nM	CHEMBL_ACT_755978
P62965	9.4	Kd	0.4	nM	CHEMBL_ACT_895116
RARB	9.3	Ki	0.5	nM	CHEMBL_ACT_194092
RARG	9.3	EC50	0.5	nM	CHEMBL_ACT_207165
RARG	9.3	EC50	0.5	nM	CHEMBL_ACT_295012
RARG	9.3	EC50	0.5	nM	CHEMBL_ACT_324972
RARG	9.3	IC50	0.5	nM	CHEMBL_ACT_379663
RARG	9.3	EC50	0.5	nM	CHEMBL_ACT_499179
RXRB	9.3	Ki	0.5	nM	CHEMBL_ACT_663251
RARG	9.3	Ki	0.5	nM	CHEMBL_ACT_809836
P22605	9.28	EC50	0.52	nM	CHEMBL_ACT_18488961
P18911	9.22	EC50	0.6	nM	CHEMBL_ACT_19252171
RARG	9.22	Ki	0.6	nM	CHEMBL_ACT_194096
RARG	9.21	IC50	0.62	nM	CHEMBL_ACT_41941
RARG	9.15	EC50	0.7	nM	CHEMBL_ACT_580466
RARG	9.15	Ki	0.7	nM	CHEMBL_ACT_75533
RARG	9.15	EC50	0.7	nM	CHEMBL_ACT_854885
RARA	9.11	IC50	0.78	nM	CHEMBL_ACT_379661
RARB	9.05	IC50	0.9	nM	CHEMBL_ACT_379662
RARA	9.05	IC50	0.89	nM	CHEMBL_ACT_41939

Target pathways

Aggregated over 7 target gene(s): RARA, RARB, RARG, PPARD, RORB, NR2C2, NR2E1.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Nuclear Receptor transcription pathway	7	NR2C2, NR2E1, PPARD, RARA, RARB, RARG, RORB
Signaling by Retinoic Acid	4	PPARD, RARA, RARB, RARG
Activation of anterior HOX genes in hindbrain development during early embryogenesis	3	RARA, RARB, RARG
Carnitine shuttle	1	PPARD
Generic Transcription Pathway	1	RORB
SUMOylation of intracellular receptors	1	RARA
RNA Polymerase II Transcription	1	RORB
Gene expression (Transcription)	1	RORB
Regulation of PTEN gene transcription	1	NR2E1
Transcriptional regulation of granulopoiesis	1	RARA
TGFBR3 expression	1	RARA
Expression of BMAL (ARNTL), CLOCK, and NPAS2	1	RORB
Interaction of NuRD complexes with transcription factors	1	NR2C2

Dominant GO biological processes

GO term	Targets
positive regulation of transcription by RNA polymerase II	7
regulation of DNA-templated transcription	7
negative regulation of transcription by RNA polymerase II	6
cell differentiation	6
negative regulation of apoptotic process	4
apoptotic process	4
cell population proliferation	4
intracellular receptor signaling pathway	4
glandular epithelial cell development	3
growth plate cartilage development	3
positive regulation of cell population proliferation	3
regulation of myelination	3
multicellular organism growth	3
negative regulation of DNA-templated transcription	3
positive regulation of DNA-templated transcription	3

Indications & clinical

Indications

45 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acne	4	MONDO:0011438	EFO:0003894
neoplasm	4	MONDO:0005070	EFO:0000616
acute promyelocytic leukemia	4	MONDO:0012883	EFO:0000224
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
rosacea	3	MONDO:0006604	EFO:1000760
myelodysplastic syndrome	3	MONDO:0018881	EFO:0000198
leukemia	3	MONDO:0005059	EFO:0000565
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
basal cell carcinoma	3	MONDO:0020804	EFO:0004193
autoimmune thrombocytopenic purpura	3	MONDO:0008558	EFO:0007160
breast neoplasm	3	MONDO:0021100	EFO:0003869
skin neoplasm	3	MONDO:0002531	EFO:0004198
lymphoma	2	MONDO:0005062	EFO:0000574
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
neuroblastoma	2	MONDO:0005072	EFO:0000621
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
melanoma	2	MONDO:0005105	EFO:0000756
actinic keratosis	2	MONDO:0005173	EFO:0002496
sclerosing cholangitis	2	MONDO:0018646	EFO:0004268
anti-neutrophil antibody associated vasculitis	2	MONDO:0005435	EFO:0004826
adenoid cystic carcinoma	2	MONDO:0004971	EFO:0000231
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
pulmonary emphysema	2	MONDO:0004849	EFO:0000464
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
anemia	2	MONDO:0002280	MONDO:0002280
kidney cancer	2	MONDO:0002367	MONDO:0002367
lung neoplasm	2	MONDO:0021117	MONDO:0008903
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0044881
myelodysplastic/myeloproliferative disease	1	MONDO:0020077	MONDO:0020077
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976
plasma cell neoplasm	1	MONDO:0004959	EFO:0000200
glioblastoma	1	MONDO:0018177	EFO:0000519
autism	0	MONDO:0005260	EFO:0003758

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 154.

Phase distribution

Phase	Trials
PHASE2	59
PHASE3	28
Not specified	15
PHASE1/PHASE2	14
PHASE1	14
PHASE4	11
PHASE2/PHASE3	7
EARLY_PHASE1	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00408278	PHASE4	COMPLETED	Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
NCT00504764	PHASE4	COMPLETED	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
NCT00835198	PHASE4	COMPLETED	Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
NCT01047189	PHASE4	COMPLETED	Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
NCT01206348	PHASE4	COMPLETED	Combination Treatment for Moderate to Severe Acne
NCT01987297	PHASE4	UNKNOWN	Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
NCT02020161	PHASE4	UNKNOWN	Clinical Guidelines for APL Treatment
NCT02200978	PHASE4	COMPLETED	A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
NCT04096742	PHASE4	UNKNOWN	Altreno for Chest Rejuvenation
NCT04548349	PHASE4	COMPLETED	Profiling the Skin Microbiome in Response to Altreno in Acne Patients
NCT07012811	PHASE4	COMPLETED	Treatment of Plane Warts With Topical and Oral Retinoids
NCT02339740	PHASE3	ACTIVE_NOT_RECRUITING	Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT06706401	PHASE3	RECRUITING	Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
NCT06787222	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome
NCT07278908	PHASE2/PHASE3	NOT_YET_RECRUITING	Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
NCT07503730	PHASE3	RECRUITING	Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
NCT07504458	PHASE3	RECRUITING	Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT00002658	PHASE3	UNKNOWN	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002701	PHASE3	UNKNOWN	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
NCT00003934	PHASE3	COMPLETED	Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
NCT00005823	PHASE3	COMPLETED	Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00005863	PHASE3	COMPLETED	Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
NCT00007631	PHASE3	COMPLETED	Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
NCT00151242	PHASE2/PHASE3	COMPLETED	Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00151255	PHASE3	COMPLETED	All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00378365	PHASE3	UNKNOWN	Acute Promyelocytic Leukemia 2006 (APL)
NCT00482833	PHASE3	COMPLETED	Phase III Trial in Acute Promyelocytic Leukemia Patients
NCT00492856	PHASE3	COMPLETED	S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
NCT00599937	PHASE3	COMPLETED	APL93: Timing of CxT and Role of Maintenance
NCT00647556	PHASE3	COMPLETED	Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage
NCT00717652	PHASE2/PHASE3	SUSPENDED	Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma
NCT00866918	PHASE3	COMPLETED	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
NCT01041833	PHASE3	UNKNOWN	Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker
NCT01067274	PHASE3	WITHDRAWN	ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
NCT01226303	PHASE3	UNKNOWN	Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
NCT01243450	PHASE3	COMPLETED	Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
NCT01406080	PHASE3	COMPLETED	A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
NCT02249767	PHASE3	COMPLETED	Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel
NCT02688140	PHASE3	COMPLETED	Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02899169	PHASE3	UNKNOWN	Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Clinical evidence (CIViC)

Variant × indication × effect (12 predictive associations from 14 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
PML::RARA Fusion	Acute Promyelocytic Leukemia	Sensitivity/Response	Arsenic Trioxide + Tretinoin	CIViC A	EID1091
NPM1 EXON 11 MUTATION	Acute Myeloid Leukemia	Sensitivity/Response	Tretinoin	CIViC B	EID137 +1
PML::RARA Fusion	Acute Promyelocytic Leukemia	Sensitivity/Response	Tretinoin	CIViC B	EID316 +1
CEBPA Mutation	Acute Myeloid Leukemia	Sensitivity/Response	Tretinoin	CIViC B	EID122
FLT3 ITD	Acute Promyelocytic Leukemia	Resistance	Anthracycline Antineoplastic Antibiotic + Tretinoin	CIViC B	EID1112
FLT3 ITD	Acute Myeloid Leukemia	Resistance	Tretinoin	CIViC B	EID127
PML B2 DOMAIN MUTATION	Acute Promyelocytic Leukemia	Resistance	Tretinoin	CIViC B	EID1092
PML K227_T233del	Acute Promyelocytic Leukemia	Resistance	Tamibarotene + Tretinoin	CIViC C	EID8175
PML::RARA Fusion AND PML A216V	Acute Promyelocytic Leukemia	Resistance	Tretinoin	CIViC C	EID1093
PML::RARA Fusion AND PML L218P	Acute Promyelocytic Leukemia	Resistance	Tretinoin	CIViC C	EID1094
ALDH1A2 Underexpression	Head And Neck Squamous Cell Carcinoma	Sensitivity/Response	Tretinoin	CIViC D	EID1115
NPM1 EXON 11 MUTATION	Acute Myeloid Leukemia	Sensitivity/Response	NSC348884 + Tretinoin	CIViC D	EID149

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

72 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Rosiglitazone	ChEMBL + PubChem	Phase 4 (approved)	PPARD, RARA, RARB, RARG
Sunitinib	PubChem	Approved	NR2C2, RARA, RARB, RARG
Acetaminophen	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
ADAPALENE	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
ALITRETINOIN	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
Alprostadil	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
Amoxicillin	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
BEXAROTENE	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
cyclosporine	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
Olanzapine	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
TAZAROTENE	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
Tolcapone	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
TRIFAROTENE	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
Zafirlukast	ChEMBL + PubChem	Phase 4 (approved)	RARA, RARB, RARG
TAMIBAROTENE	ChEMBL	Phase 4 (approved)	RARA, RARB, RARG
CONESSINE	ChEMBL	Phase 2	RARA, RARB, RARG
GLIQUIDONE	ChEMBL	Phase 2	RARA, RARB, RARG
Atorvastatin	PubChem	Approved	RARA, RARB, RARG
Bosentan	PubChem	Approved	RARA, RARB, RARG
Calcitriol	PubChem	Approved	RARA, RARB, RARG
Carprofen	PubChem	Approved	RARA, RARB, RARG
Diclofenac	PubChem	Approved	RARA, RARB, RARG
ethinyl estradiol	PubChem	Approved	RARA, RARB, RARG
Repaglinide	PubChem	Approved	RARA, RARB, RARG
rifampin	PubChem	Approved	RARA, RARB, RARG
Simvastatin	PubChem	Approved	RARA, RARB, RARG
Ticlopidine	PubChem	Approved	RARA, RARB, RARG
Verapamil	PubChem	Approved	RARA, RARB, RARG
TROGLITAZONE	ChEMBL	Phase 4 (approved)	RARB, RARG
Retinol	PubChem	Approved	NR2C2, RARA
Rivaroxaban	PubChem	Approved	RARB, RARG
CAFFEINE	ChEMBL + PubChem	Phase 4 (approved)	NR2E1
PROPAFENONE	ChEMBL + PubChem	Phase 4 (approved)	NR2E1
PROPRANOLOL	ChEMBL + PubChem	Phase 4 (approved)	NR2E1
SELADELPAR	ChEMBL + PubChem	Phase 4 (approved)	PPARD
TADALAFIL	ChEMBL + PubChem	Phase 4 (approved)	NR2E1
BERBERINE	ChEMBL	Phase 4 (approved)	PPARD
ELAFIBRANOR	ChEMBL	Phase 4 (approved)	PPARD
IBUPROFEN	ChEMBL	Phase 4 (approved)	RARB
KETOCONAZOLE	ChEMBL	Phase 4 (approved)	RARB
PEMAFIBRATE	ChEMBL	Phase 4 (approved)	PPARD
PIOGLITAZONE	ChEMBL	Phase 4 (approved)	PPARD
RACECADOTRIL	ChEMBL	Phase 4 (approved)	RARG
TROVAFLOXACIN	ChEMBL	Phase 4 (approved)	RARB
ALEGLITAZAR	ChEMBL	Phase 3	PPARD
BEZAFIBRATE	ChEMBL	Phase 3	PPARD
GAMOLENIC ACID	ChEMBL	Phase 3	PPARD
ICOSAPENT	ChEMBL	Phase 3	PPARD
LANIFIBRANOR	ChEMBL	Phase 3	PPARD
NAMODENOSON	ChEMBL	Phase 3	PPARD
CEP-11981	ChEMBL	Phase 2	NR2C2
DEXPROPRANOLOL	ChEMBL	Phase 2	NR2E1
DIHOMO-GAMMA-LINOLENIC ACID	ChEMBL	Phase 2	PPARD
FARGLITAZAR	ChEMBL	Phase 2	PPARD
GW501516	ChEMBL	Phase 2	PPARD
GW590735	ChEMBL	Phase 2	PPARD
INDEGLITAZAR	ChEMBL	Phase 2	PPARD
LEVOPROPRANOLOL	ChEMBL	Phase 2	NR2E1
LINOLEIC ACID	ChEMBL	Phase 2	PPARD